Hubei Guangji Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 522.49 million compared to CNY 536.28 million a year ago. Revenue was CNY 522.49 million compared to CNY 536.28 million a year ago.

Net loss was CNY 66.98 million compared to net income of CNY 19.91 million a year ago. Basic loss per share from continuing operations was CNY 0.1892 compared to basic earnings per share from continuing operations of CNY 0.0564 a year ago. Diluted loss per share from continuing operations was CNY 0.1892.